FDA’s Latest Guidance On Chemical Analysis: What Medical Device Manufacturers Need To Know

The evolving regulatory landscape for medical devices continues to place greater emphasis on material safety, chemical characterization, and toxicological risk assessment. In September 2024, the U.S. Food and Drug Administration (FDA) released its draft guidance titled “Chemical Analysis for Biocompatibility Assessment of Medical Devices”, introducing a more structured and science-driven approach to evaluating chemical risks associated with medical devices.

This guidance significantly impacts premarket submissions such as 510(k), PMA, and De Novo applications, requiring manufacturers to adopt robust analytical chemistry strategies and risk-based evaluation frameworks.

Maven Regulatory Solutions provides end-to-end support in chemical characterization, extractables and leachables (E&L) studies, and toxicological risk assessment, ensuring seamless FDA compliance and accelerated approvals.

Understanding Chemical Characterization in Medical Devices

Chemical characterization involves identifying and quantifying chemical substances released from medical devices under clinically relevant conditions.

It is a cornerstone of biocompatibility assessment under ISO 10993 standards, and in certain cases, it can replace biological testing when supported by Toxicological Risk Assessment (TRA) as per ISO 10993-17.

Key Applications

• Evaluating material and manufacturing changes 
• Supporting chemical equivalence assessments 
• Identifying extractables and leachables (E&L) 
• Reducing reliance on animal testing 

Key Highlights of FDA Draft Guidance (2024)

1. Scope and Applicability

The guidance applies to:

• Devices with direct or indirect patient contact 
• Implants, catheters, infusion systems, wound dressings 
• Combination products with chemical exposure risks 
• Devices using novel materials or processes 

2. Risk-Based Study Approach

The FDA emphasizes a risk-based framework, requiring:

• Detailed material composition analysis 
• Identification of cohorts of concern (e.g., genotoxic impurities) 
• Evaluation of worst-case exposure scenarios 

Risk-Based Approach Overview

3. Extractables & Leachables (E&L) Testing

The guidance outlines advanced methodologies for chemical identification and quantification.

Analytical Techniques

Key Testing Considerations

• Use worst-case extraction conditions (ISO 10993-18 aligned) 
• Perform non-targeted screening for unknown compounds 
• Conduct targeted analysis for compounds above thresholds  
• Evaluate material-specific extractions 

4. Toxicological Risk Assessment (TRA)

TRA is essential to determine the safety of identified compounds.

Key Components

• Comparison with Permitted Daily Exposure (PDE) 
• Application of Threshold of Toxicological Concern (TTC) 
• Use of in silico toxicology tools 
• Integration of compound-specific toxicity data 

5. Extraction Conditions and Study Design

• Align with ISO 10993-18 extraction protocols 
• Evaluate three independent batches for variability 
• Justify any deviations scientifically 

6. Alternative Approaches

The FDA allows flexibility with:

• In silico modeling and predictive toxicology 
• Use of existing literature and historical data 
• Reduced testing with scientific justification 

Implications for Medical Device Manufacturers

Key Industry Impacts

Major Considerations

• Enhanced scrutiny in FDA reviews 
• Increased reliance on analytical chemistry data 
• Integration of toxicology and risk assessment frameworks
• Need for cross-functional regulatory strategies 

Best Practices for FDA Compliance

• Early Chemical Characterization in R&D 
• Alignment with ISO 10993-18 and ISO 10993-17 
• Robust E&L testing strategies 
• Comprehensive documentation and reporting 
• Collaboration with toxicology and regulatory experts 

Latest Trends in Medical Device Chemical Analysis (2025–2026)

• Adoption of AI-driven chemical characterization tools 
• Growth in in silico toxicology and predictive modeling 
• Increased focus on sustainable and safer materials 
• Integration of digital regulatory submissions and data traceability 
• Expansion of global harmonization in biocompatibility standards 

How Maven Regulatory Solutions Supports Compliance

Maven Regulatory Solutions offers specialized expertise in chemical analysis, toxicology, and regulatory compliance.

Core Services

1. Chemical Characterization & E&L Studies

Comprehensive testing aligned with FDA and ISO requirements.

2. Toxicological Risk Assessment (TRA)

Evaluation using PDE, TTC, and advanced toxicology models.

3. Regulatory Strategy & Submission Support

Preparation of 510(k), PMA, and De Novo documentation.

4. In Silico Toxicology & Data Analysis

Advanced modeling for risk prediction and assessment.

5. Compliance Documentation

Preparation of technical reports and regulatory justifications.

Conclusion

The FDA’s latest draft guidance on chemical analysis represents a significant shift toward more rigorous, data-driven biocompatibility evaluation for medical devices. By emphasizing chemical characterization, E&L testing, and toxicological risk assessment, the FDA aims to enhance patient safety and regulatory consistency.

Medical device manufacturers must proactively adapt to these evolving expectations by integrating advanced analytical techniques, robust risk assessment frameworks, and expert regulatory strategies.

Maven Regulatory Solutions stands as a trusted partner, delivering end-to-end support in chemical analysis, toxicology, and regulatory compliance, ensuring successful product approvals and global market access.

Frequently Asked Questions

1. What is FDA chemical analysis guidance for medical devices?

It provides recommendations for chemical characterization and biocompatibility assessment.

2. What are extractables and leachables (E&L)?

Chemicals are released from device materials during use.

3. What is TRA in medical devices?

A toxicological risk assessment evaluating safety of chemical exposure.

4. Which standards apply to chemical characterization?

ISO 10993-17 and ISO 10993-18.

5. How can Maven support FDA compliance?

Through E&L testing, toxicology assessment, and regulatory submissions.